{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:12:14Z","timestamp":1758636734498},"reference-count":58,"publisher":"Informa UK Limited","issue":"13","funder":[{"name":"internal funds"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.2217\/fon.15.86","type":"journal-article","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T14:48:49Z","timestamp":1436539729000},"page":"1947-1959","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review"],"prefix":"10.1080","volume":"11","author":[{"given":"Sara","family":"Pusceddu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2018,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2018,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Festinese","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2019,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bregant","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2018,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Lorenzoni","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2019,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2019,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[{"name":"Department of Pathology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2019,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Concas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2018,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Formisano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2018,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Leuzzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2018,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[{"name":"Department of Surgery &amp; liver transplantation,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2019,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Buzzoni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,ENETS Center of Excellence,Fondazione IRCCS \u2018Istituto Nazionale dei Tumori\u2018,\rMilan,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,7,10]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70410-2"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23549"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181ce1447"},{"key":"e_1_3_3_7_1","volume-title":"WHO Classification of Tumours, Volume 2 (4th Edition)","author":"Swerdlow SH","year":"2010","unstructured":"Swerdlow SH , CampoE, HarrisNLet al. WHO Classification of Tumours, Volume 2 (4th Edition) . IARC Press, Lyon, France (2010)."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ec124e"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1385\/EP:14:4:293"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2007.07.202"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2013.410176"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/172460080401900407"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.12.001"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9148-z"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0666"},{"key":"e_1_3_3_17_1","unstructured":"ClinicalTrial.gov\n. https:\/\/clinicaltrial.gov."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335597"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04174.x"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2007.09.006"},{"key":"e_1_3_3_23_1","first-page":"31","article-title":"A multicenter, randomized, blinded, Phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumours (NET) with disease-related symptoms inadeguately controlled by somatostatin analogs","author":"Wolin EM","year":"2013","unstructured":"Wolin EM , JarzabB, EriksonBet al. A multicenter, randomized, blinded, Phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumours (NET) with disease-related symptoms inadeguately controlled by somatostatin analogs. J. Clin. Oncol.31, Abstract 4031 (2013).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.142"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00481-7"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds295"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260804"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.11.1255"},{"key":"e_1_3_3_29_1","first-page":"627","article-title":"Treatment of metastasized midgut carcinoids with dacarbazine","volume":"90","author":"Ritzel U","year":"1995","unstructured":"Ritzel U , LeonhardtUF, StockmannF, RamadoriG. Treatment of metastasized midgut carcinoids with dacarbazine. Am. J. Gastroenterol.90, 627\u2013631 (1995).","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690325"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25425"},{"key":"e_1_3_3_32_1","first-page":"14","article-title":"A retrospective study of capecitabine\/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy","volume":"10","author":"Saif MW","year":"2013","unstructured":"Saif MW , KaleyK, BrennanM, GarconMC, RodriguezG, RodriguezT. A retrospective study of capecitabine\/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP10, 14 (2013).","journal-title":"JOP"},{"key":"e_1_3_3_33_1","first-page":"32","article-title":"Prospective Phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately and well-differentiately metastatic neuroendocrine tumors","author":"Fine RL","year":"2014","unstructured":"Fine RL , GulatiAP, TsushimaDet al. Prospective Phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately and well-differentiately metastatic neuroendocrine tumors. J. Clin. Oncol.32, Abstract 179 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1476"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365514"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.06.009"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds276"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200007000-00015"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00181765"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1989-4"},{"key":"e_1_3_3_41_1","first-page":"610","article-title":"Tumour response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr C","year":"2002","unstructured":"Waldherr C , PlessM, MaeckeHRet al. Tumour response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med.43, 610\u2013616 (2002).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.016"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1118\/1.4824318"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.3413\/Nukmed-0581-13-05"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2578-5"},{"key":"e_1_3_3_47_1","first-page":"S117","article-title":"Monitoring of perfusion changes after systemic versus selective arterial 177Lu\/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy using contrast-enhanced ultrasound in liver metastatic neuroendocrine cancer","volume":"38","author":"Giesel F","year":"2011","unstructured":"Giesel F . Monitoring of perfusion changes after systemic versus selective arterial 177Lu\/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy using contrast-enhanced ultrasound in liver metastatic neuroendocrine cancer. Eur. J. Nucl. Med. Mol. Imaging38, S117 (2011).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200609"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu345.1"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28726"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu345.12"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1757-5"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3147"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0287"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-184"},{"key":"e_1_3_3_59_1","first-page":"30","article-title":"A multi-institutional Phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumour (PNET): results of a planned interim efficacy analysis","author":"Hobday TJ","year":"2012","unstructured":"Hobday TJ , QinR, ReidyDet al. A multi-institutional Phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumour (PNET): results of a planned interim efficacy analysis. J. Clin. Oncol.30, Abstract 4047 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_60_1","volume-title":"3rd Annual Meeting of the North American NeuroEndocrine Tumor Society","author":"Yao J","year":"2010","unstructured":"Yao J , PhanA, HessKet al. Randomized run-in study of bevacizumab and everolimus in low- to intermediate-grade neuroendocrine tumor (LGNETs) using perfusion CT (pCT) as functional biomarker. Presented at: 3rd Annual Meeting of the North American NeuroEndocrine Tumor Society. Santa Fe, NM, USA, 29\u201330 October 2010."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.86","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:26Z","timestamp":1719125126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.86"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":58,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.2217\/fon.15.86"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.86","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}